Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016
Clinical Endocrinology · 2024
DOI: 10.1111/cen.15060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Steve Orme und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, St James's University Hospital Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Acromegaly, Human Growth Hormone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma, Ipsen Biopharmaceuticals, Leeds Hospital Charitable Foundation.
Abstract (Originalsprache)
Context
Epidemiological studies involving patients with acromegaly have yielded conflicting results regarding cancer incidence and causes of mortality in relation to control of growth hormone (GH) excess.
Objective
The objective of this retrospective cohort study is to clarify these questions and identify goals for treatment and monitoring patients.
Methods
We studied 1845 subjects from the UK Acromegaly Register (1970–2016), obtaining cancer standardised incidence rates (SIR) and all causes standardised mortality rates (SMR) from UK Office for National Statistics, to determine the relationship between causes of mortality—age at diagnosis, duration of disease, post‐treatment and mean GH levels.
Results
We found an increased incidence of all cancers (SIR, 1.38; 95% CI: 1.06–1.33, p < .001), but no increase in incidence of female breast, thyroid, colon cancer or any measure of cancer mortality. All‐cause mortality rates were increased (SMR, 1.35; 95% CI: 1.24–1.46, p < .001), as were those due to vascular and respiratory diseases. All‐cause, all cancer and cardiovascular deaths were highest in the first 5 years following diagnosis. We found a positive association between post‐treatment and mean treatment GH levels and all‐cause mortality ( p < .001 and p < .001), which normalised with posttreatment GH levels of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, St James's University Hospital Leeds, Leeds, UK.
- Population Health Science Institute, Newcastle University, Royal Victoria Infirmary, Newcastle Upon Tyne, UK.
- Society for Endocrinology, Bristol, UK.
- Department of Endocrinology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
- Department of Endocrinology, Christie Hospital NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, UK.
- Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.
Förderung
- Novartis Pharma
- Ipsen Biopharmaceuticals
- Leeds Hospital Charitable Foundation
- Clinical Endocrinology Trust
- Pfizer UK
Zitieren
APA
Orme, S., McNally, R., James, P. W., Davis, J., Ayuk, J., Higham, C., Wass, J., & UK Acromegaly Register Study Group (2024). Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016. Clinical Endocrinology. https://doi.org/10.1111/cen.15060
Vancouver
Orme S, McNally R, James PW, Davis J, Ayuk J, Higham C, et al. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016. Clinical Endocrinology. 2024. doi:10.1111/cen.15060
BibTeX
@article{Orme2024,
author = {Orme, Steve and McNally, Richard and James, Peter W and Davis, Jessica and Ayuk, John and Higham, Claire and Wass, John and UK Acromegaly Register Study Group, UK Acromegaly Register Study Group},
title = {Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels—A retrospective analysis from the UK Acromegaly Register 1970–2016},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.15060}
}
EUVIMED